
Anixa Biosciences ANIX
$ 3.01
1.35%
Quarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences EV/EBITDA Ratio 2011-2026 | ANIX
Annual EV/EBITDA Ratio Anixa Biosciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.25 | -5.26 | -6.54 | -4.93 | -4.72 | -12.5 | -36.6 | -7.89 | -6.32 | -9.6 | -4.59 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.25 | -36.6 | -9.2 |
EV/EBITDA Ratio of other stocks in the Diagnostics research industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
28.1 | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
0.387 | - | -6.23 % | $ 30.6 M | ||
|
Co-Diagnostics
CODX
|
3.62 | $ 1.63 | -1.21 % | $ 2.17 M | ||
|
Agilent Technologies
A
|
27.4 | $ 114.87 | -0.65 % | $ 34.9 B | ||
|
Accelerate Diagnostics
AXDX
|
-5.56 | - | -61.36 % | $ 2.46 M | ||
|
Chembio Diagnostics
CEMI
|
-1.23 | - | 0.22 % | $ 16.8 M | ||
|
Aspira Women's Health
AWH
|
-2.63 | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-26.9 | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
-21.2 | $ 24.7 | -1.12 % | $ 686 M | ||
|
Check-Cap Ltd.
CHEK
|
-0.674 | - | - | $ 9.42 M | ||
|
Enzo Biochem
ENZ
|
58.3 | - | -8.98 % | $ 14.8 K | ||
|
CareDx, Inc
CDNA
|
-100 | $ 21.91 | 0.27 % | $ 1.17 B | ||
|
Illumina
ILMN
|
70.5 | $ 126.92 | -1.24 % | $ 20.2 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-73.4 | - | - | $ 562 M | ||
|
DermTech
DMTK
|
-2.44 | - | -11.32 % | $ 2.94 M | ||
|
Exact Sciences Corporation
EXAS
|
-20.8 | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
2.58 | $ 15.3 | -1.92 % | $ 463 M | ||
|
HTG Molecular Diagnostics
HTGM
|
-1.42 | - | -20.0 % | $ 1.06 M | ||
|
Lantheus Holdings
LNTH
|
-187 | $ 83.55 | -0.67 % | $ 5.64 B | ||
|
Global Cord Blood Corporation
CO
|
-3.52 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-13.6 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-2.67 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-2.67 | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
22 | $ 166.79 | -2.59 % | $ 8.27 B | ||
|
National Research Corporation
NRC
|
21 | $ 16.84 | -1.58 % | $ 377 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
20.8 | - | - | $ 10.7 B | ||
|
Guardant Health
GH
|
-28.8 | $ 83.09 | -6.11 % | $ 10.4 B | ||
|
Koninklijke Philips N.V.
PHG
|
55.6 | $ 27.12 | -1.53 % | $ 20 B | ||
|
Precipio
PRPO
|
-1.8 | $ 31.75 | 3.42 % | $ 51 M | ||
|
Personalis
PSNL
|
-7.07 | $ 5.5 | -7.72 % | $ 326 M | ||
|
Heska Corporation
HSKA
|
141 | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
-6.02 | $ 1.93 | - | $ 8.54 M | ||
|
Senseonics Holdings
SENS
|
-13.8 | $ 7.18 | -1.24 % | $ 300 M | ||
|
Medpace Holdings
MEDP
|
30.7 | $ 409.65 | -2.78 % | $ 11.8 B | ||
|
QIAGEN N.V.
QGEN
|
13.2 | - | - | $ 10.6 B | ||
|
Motus GI Holdings
MOTS
|
0.351 | - | -34.28 % | $ 263 K | ||
|
Biomerica
BMRA
|
-6.24 | $ 2.19 | 0.46 % | $ 5.03 M | ||
|
Thermo Fisher Scientific
TMO
|
19.3 | $ 470.22 | 0.47 % | $ 177 B | ||
|
ICON Public Limited Company
ICLR
|
38 | $ 102.49 | -0.7 % | $ 8.45 B | ||
|
Laboratory Corporation of America Holdings
LH
|
8.7 | $ 259.57 | -1.47 % | $ 21.6 B | ||
|
Trinity Biotech plc
TRIB
|
12.6 | $ 0.61 | -4.93 % | $ 61.9 M | ||
|
Neogen Corporation
NEOG
|
40.3 | $ 9.34 | -1.16 % | $ 2.03 B | ||
|
Celcuity
CELC
|
-2.38 | $ 120.07 | -4.46 % | $ 5.61 B | ||
|
Twist Bioscience Corporation
TWST
|
-23.6 | $ 59.15 | -3.03 % | $ 3.54 B | ||
|
NeoGenomics
NEO
|
-33.5 | $ 9.02 | 4.76 % | $ 1.16 B | ||
|
Myriad Genetics
MYGN
|
-17.2 | $ 4.84 | 0.21 % | $ 448 M | ||
|
Natera
NTRA
|
-19.5 | $ 200.17 | -2.06 % | $ 19.7 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.51 | $ 195.05 | -0.8 % | $ 21.7 B | ||
|
Invitae Corporation
NVTA
|
-10.7 | - | - | $ 21.2 M | ||
|
OpGen
OPGN
|
0.274 | - | -16.95 % | $ 1.54 M |